The Patent Finder

Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH

Baxalta Incorporated

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 61/384,209, filed Sep 17, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,795,658Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH
In force
 · High confidence
Baxalta GmbH and Baxalta IncorporatedIn force
High confidence
US 9,855,331Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH
In force
 · High confidence
Baxalta GmbH and Baxalta IncorporatedIn force
High confidence
Application 15/859,108Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH
Abandoned
Abandoned Apr 23, 2020
Baxalta GmbH and Baxalta IncorporatedAbandonedAbandoned Apr 23, 2020
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Baxalta Incorporated.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited